Apply for Funding

CPRIT offers several funding opportunities for promising cancer research, product development, and prevention programs. All funding opportunities are announced through formal Requests for Applications (RFAs) and applications must be submitted through the online application receipt system.

Learn more about the grants process.

Individual Investigator Research Awards

Program Academic Research
RFA Status Open
Description

Supports applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer. Areas of interest include laboratory research, translational studies, and/or clinical investigations. Competitive renewal applications accepted.

Award: Up to $350,000 per year. Exceptions permitted if extremely well justified; maximum duration: 3 years.

Review Cycle Fiscal Year 2023 - Cycle 1
RFA Release January 14, 2022
Application Receipt March 16, 2022 - June 08, 2022
Application Review June 2022 - February 2023
Award Notification February 2023

Individual Investigator Research Awards for Cancer in Children and Adolescents

Program Academic Research
RFA Status Open
Description

Supports applications for innovative research projects addressing questions that will advance knowledge of the causes, prevention, progression, detection, or treatment of cancer in children and adolescents. Laboratory, clinical, or population-based studies are all acceptable. CPRIT expects the outcome of the research to reduce the incidence, morbidity, or mortality from cancer in children and/or adolescents in the near or long term. Competitive renewal applications accepted.

Award: Up to $350,000 per year. Applicants that plan on conducting a clinical trial as part of the project may request up to $500,000 in total costs. Exceptions permitted if extremely well justified; maximum duration: 4 years.

Review Cycle Fiscal Year 2023 - Cycle 1
RFA Release January 14, 2022
Application Receipt March 16, 2022 - June 08, 2022
Application Review June 2022 - February 2023
Award Notification February 2023

Individual Investigator Research Awards for Clinical Translation

Program Academic Research
RFA Status Open
Description

Supports applications that propose innovative cancer clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial. Areas of interest include clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices. Clinical trial must be planned to begin when contract is awarded.

Award: Up to $500,000 per year. Maximum duration: 4 years. Exceptions permitted if extremely well justified.

Review Cycle Fiscal Year 2023 - Cycle 1
RFA Release January 14, 2022
Application Receipt March 16, 2022 - June 08, 2022
Application Review June 2022 - February 2023
Award Notification February 2023

Individual Investigator Research Awards for Computational Systems Biology of Cancer

Program Academic Research
RFA Status Open
Description

Supports applications for innovative mathematical and/or computational research projects addressing questions that will advance current knowledge in the (a) mechanisms that tie altered gene expression and downstream molecular mechanisms to functional cancer phenotypes and/or (b) mechanisms that tie tumor morphology to functional cancer phenotypes and/or mechanisms that tie treatment sequence and combination to evolving functional cancer phenotypes (that emerge as a result of treatment selection). 

Award: Up to $400,000 in total costs per year for up to 3 years. Exceptions permitted if  extremely well justified.

Review Cycle Fiscal Year 2023 - Cycle 1
RFA Release January 14, 2022
Application Receipt March 16, 2022 - June 08, 2022
Application Review June 2022 - February 2023
Award Notification February 2023

Individual Investigator Research Awards for Prevention and Early Detection

Program Academic Research
RFA Status Open
Description

Supports applications which propose clinical and population-based projects designed to develop effective prevention and early detection interventions to reduce cancer risk, mortality, and morbidity among Texans. Projects that propose such research collaborations with existing CPRIT Prevention Program awardees including the CPRIT funded Texas Collaborative Center for Hepatocellular Cancer are strongly encouraged. 

Award: Up to $400,000 per year. Exceptions permitted if extremely well justified; maximum duration: 5 years.

Review Cycle Fiscal Year 2023 - Cycle 1
RFA Release January 14, 2022
Application Receipt March 16, 2022 - June 08, 2022
Application Review June 2022 - February 2023
Award Notification February 2023

Company Relocation Product Development Awards

Instructions for Applicants

Program Product Development Research
RFA Status Open
Description

This award mechanism seeks to support early stage “startup” and established companies in the development of innovative products and services with significant potential impact on cancer patient care. The proposed project must further the development of new products or services for the diagnosis, treatment, or prevention of cancer; must foster a robust biotechnology industry ecosystem; or must fulfill a critical unmet need in cancer patient care. Companies must relocate to Texas upon receipt of award.

CPRIT held a webinar on November 16, 2021 which provided pro tips and contained a Q&A session on how to submit a successful company application. View Webinar Resources

Read More

Review Cycle Fiscal Year 2022 - Cycle 2
RFA Release November 03, 2021
Application Receipt December 01, 2021 - January 26, 2022
Application Review March 2022
Award Notification August 2022

Seed Awards for Product Development Research

Instructions for Applicants

Program Product Development Research
RFA Status Open
Description

This award mechanism seeks to support early-stage "startup" companies in the development of innovative products, services, and infrastructure with significant potential impact on cancer patient care.

The proposed project must further the development of new products for the diagnosis, treatment, or prevention of cancer; must establish infrastructure that is critical to the development of a robust cancer biotech industry; or must fill a treatment or research gap. Company applicants must be headquartered in Texas or be willing to relocate to Texas upon receipt of award.

CPRIT held a webinar on November 16, 2021 which provided pro tips and contained a Q&A session on how to submit a successful company application. View Webinar Resources

Read More

Review Cycle Fiscal Year 2022 - Cycle 2
RFA Release November 03, 2021
Application Receipt December 01, 2021 - January 26, 2022
Application Review March 2022
Award Notification August 2022

Texas Company Product Development Awards

Instructions for Applicants

Program Product Development Research
RFA Status Open
Description

This award mechanism seeks to support early-stage "startup" and established companies in the development of innovative products, services, and infrastructure with significant potential impact on cancer patient care.

The proposed project must further the development of new products for the diagnosis, treatment, or prevention of cancer; must establish infrastructure that is critical to the development of a robust cancer biotech industry; or must fill a treatment or research gap. Companies must be headquartered in Texas.

CPRIT held a webinar on November 16, 2021 which provided pro tips and contained a Q&A session on how to submit a successful company application. View Webinar Resources

Read More

Review Cycle Fiscal Year 2022 - Cycle 2
RFA Release November 03, 2021
Application Receipt December 01, 2021 - January 26, 2022
Application Review March 2022
Award Notification August 2022

Evidence-Based Cancer Prevention Services

Revised: 12/14/2021

Instructions for Applicants

Program Prevention
RFA Status Open
Description

This award mechanism seeks to fund projects that will deliver evidence-based cancer prevention and control clinical services. Priority will be given to projects that propose to address CPRIT areas of emphasis and serve areas of the state not well addressed by current CPRIT funded projects. Only proposals for new projects are eligible under this mechanism. Eligible applications must include the delivery of services to nonmetropolitan (rural) and medically underserved counties in the state.

Award: Maximum of $1M; Maximum duration of 36 months.

Review Cycle Fiscal Year 2022 - Cycle 2
RFA Release October 19, 2021
Application Receipt November 15, 2021 - February 09, 2022
Application Review March 2022 - July 2022
Award Notification August 2022

Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

Revised: 12/14/2021

Instructions for Applicants

Program Prevention
RFA Status Open
Description

This award mechanism seeks to support the coordination and expansion of evidence based services to prevent cancer in underserved populations who do not have adequate access to cancer prevention interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Projects should identify cancers that cause the most burden in the community and use evidence-based models shown to work in similar communities to prevent and control these cancers. For the first expansion application, eligible applicants should propose to expand their programs to include additional types of prevention clinical services and/or an expansion of current clinical services into additional counties. For a subsequent expansion, additional clinical services and/or expansion to additional counties is optional; the number of clinical services delivered must be increased substantially if no further geographic or clinical service expansion is proposed.

Initial Expansion: up to $2M over 36 months

Maintenance Expansion: up to $2.5M over 60 months

Review Cycle Fiscal Year 2022 - Cycle 2
RFA Release October 19, 2021
Application Receipt November 15, 2021 - February 09, 2022
Application Review March 2022 - July 2022
Award Notification August 2022

Tobacco Control and Lung Cancer Screening

Instructions for Applicants

Program Prevention
RFA Status Open
Description

This award mechanism seeks to fund programs on tobacco prevention and cessation, as well as screening for early detection of lung cancer. Through release of this RFA, CPRIT’s goal is to stimulate more programs across the state, thereby providing greater access for underserved populations and reducing the incidence and mortality rates of tobacco-related cancers. This RFA seeks to promote and deliver evidence-based programming designed to significantly increase tobacco cessation among adults and/or prevent tobacco use by youth.

Award: Maximum of $1 M; Maximum duration of 36 months

Review Cycle Fiscal Year 2022 - Cycle 2
RFA Release October 19, 2021
Application Receipt November 15, 2021 - February 09, 2022
Application Review March 2022 - July 2022
Award Notification August 2022

Texas Regional Excellence in Cancer Award (TREC)

Instructions for Applicants

Program Academic Research
RFA Status Open
Description

Solicits applications to strengthen cancer research at institutions located in regions of Texas that have historically received low levels of peer reviewed cancer research funding.

Award: Up to $6,000,000 (total costs); Maximum duration: 5 years.

Review Cycle Fiscal Year 2023 - Cycle 1
RFA Release September 27, 2021
Application Receipt May 16, 2022 - September 08, 2022
Application Review September 2022 - November 2022
Award Notification January 2023

Recruitment of Established Investigators

Instructions for Applicants

Program Academic Research
RFA Status Open
Description

Recruits outstanding senior research faculty with distinguished professional careers and established cancer research programs to academic institutions in Texas.

Award: Up to $6 million over a period of five years.

Review Cycle Fiscal Year 2022 - Cycle 1
RFA Release June 22, 2021
Application Receipt June 22, 2021 - June 20, 2022
Application Review Continuous
Award Notification Continuous

Recruitment of First-Time, Tenure-Track Faculty Members

Instructions for Applicants

Program Academic Research
RFA Status Open
Description

Supports very promising emerging investigators, pursuing their first faculty appointment in Texas, who have the ability to make outstanding contributions to the field of cancer research.

Award: Up to $2 million up to a period of five years.

Review Cycle Fiscal Year 2022 - Cycle 1
RFA Release June 22, 2021
Application Receipt June 22, 2021 - June 20, 2022
Application Review Continuous
Award Notification Continuous

Recruitment of Rising Stars

Instructions for Applicants

Program Academic Research
RFA Status Open
Description

Recruits outstanding early-stage investigators to Texas, who have demonstrated the promise for continued and enhanced contributions to the field of cancer research.

Award: Up to $4 million over a period of five years.

Review Cycle Fiscal Year 2022 - Cycle 1
RFA Release June 22, 2021
Application Receipt June 22, 2021 - June 20, 2022
Application Review Continuous
Award Notification Continuous